[HTML][HTML] Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - Springer
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, GL Su - Thrombosis Journal, 2021 - search.proquest.com
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
[HTML][HTML] Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - ncbi.nlm.nih.gov
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
[PDF][PDF] Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, G Liu, B Su - 2021 - scienceopen.com
Background: Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
[HTML][HTML] Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - thrombosisjournal.biomedcentral …
Anticoagulation in hospitalized COVID-19 patients has been associated with survival
benefit; however, the optimal anticoagulant strategy has not yet been defined. The objective …
benefit; however, the optimal anticoagulant strategy has not yet been defined. The objective …
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis.
S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - search.ebscohost.com
Background: Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis.
S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - go.gale.com
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis.
S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - europepmc.org
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, G Liu, B Su - Thrombosis journal, 2021 - pubmed.ncbi.nlm.nih.gov
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
[PDF][PDF] Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
S Zhang, Y Li, G Liu, B Su - 2021 - thrombosisjournal.biomedcentral …
Background: Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …